Table 1.
List of HLA-restricted and non-HLA restricted T cell cancer immunotherapies in clinical trials targeting many different antigens.
| T Cell Therapies | Antigen/Type | Disease | HLA Subtype | Status | Reference/Clinical Trial Identifier |
|---|---|---|---|---|---|
| TCR-T | KK-LC-1/cancer testis antigen Kita-kyushu Lung Cancer Antigen 1 |
Gastric, breast, cervical, lung, other KK-LC-1 and other positive epithelial cancers | HLA-A01:01 | Phase I |
NCT05483491 NCT05035407 NCT03778814 |
| E7 TCR cells | HPV-16 E7 | Human papillomavirus (HPV)-16+ cancers (cervical, vulvar, vaginal, penile, anal, and oropharyngeal cancers | HLA-A02:01 | phase I/II | NCT02858310 |
| TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR | MCPyV T | Merkel cell cancer | HLA-A02 | phase I/II trial | NCT03747484 |
| LMP2 Antigen-specific TCR T cells | LMP2 | Recurrent and metastatic nasopharyngeal carcinoma | HLA-A2, HLA-A11, HLA-A24 | Phase 1 | NCT03925896 |
| NY-ESO-1 TCR-T | NY-ESO-1 | Advanced soft tissue sarcoma | HLA-A 02/01 | Recruiting | NCT05620693 |
| TCR-T therapy | KRAS G12V or G12D | Pancreatic cancer | HLA-A*11:01 | Phase 1 | NCT05438667 |
| EBV-Specific Anti-PD1 TCR-T Cells | EBV antigen | Head and neck squamous cell carcinoma | Unknown | Phase I/II trial | NCT04139057 |
| Tumor-specific TCR-T cells | Patient specific | Solid tumor | Unknown | Phase 1 | NCT03891706 |
| HPV TCR-T | HPV E6 | HPV-positive head and neck carcinoma or cervical cancer | Unknown | Phase 1 | NCT03578406 |
| TCR-transduced T cells | TSA-reactive TCR-engineered T cells | Malignant epithelial neoplasms | Unknown | Phase 1 | NCT04520711 |
| CRTE7A2-01 TCR-T Cell | HPV16 | Cervical, anal, head and neck cancers |
HLA-A*02:01 | Phase 1 | NCT05122221 |
| MC2 TCR T cells | MAGE-C2 | Melanoma melanoma, uveal head and neck cancer |
HLA-A2 | Phase 1/2 | NCT04729543 |
| Neoantigen specific TCR-T cells | Patient specific | Gynecologic cancer colorectal, pancreatic cancer, non-small cell lung cancer, cholangiocarcinoma, ovarian cancer, ovary neoplasm, squamous cell lung cancer, adenocarcinoma of lung, adenosquamous cell lung cancer |
Unknown | Phase I/II | NCT05292859 |
| KSH01-TCR-T cells | Unknown | Refractory/recurrent solid tumors | HLA-A*02 | Early Phase 1 | NCT05539833 |
| Neoantigen specific TCR-T cell | KRAS G12D, KRAS G12V, TP53 R175H, TP53 R248W, TP53 Y220C, EGFR E746-A750del |
Gynecologic, colorectal, pancreatic, non-small cell lung cancer, cholangiocarcinoma ovarian, endometrial cancer, ovary neoplasm, squamous cell lung cancer, adenocarcinoma of lung, adenosquamous cell lung cancer |
HLA-A*11:01 HLA-C*08:02 HLA-A*11:01 HLA-C*01:02 HLA-A*02:01, HLA-DRB1*13:01, HLA-A*68:01, HLA-DRB3*02:02, HLA-DPA1*02:01, DPB1*01:01 |
Phase I/II | NCT05194735 |
| KK-LC-1 TCR T | KK-LC-1 | Gastric, breast, cervical, lung cancer | HLA-A01:01 | Phase 1 | NCT05035407 |
| FH-TCR-Tᴍsʟɴ cells | Mesothelin | Metastatic pancreatic ductal adenocarcinoma | HLA-A*02:01 | Phase 1 | NCT04809766 |
| NY-ESO-1 T cell receptor (TCR) engineered T cells | NY-ESO-1 | Ovarian, Fallopian tube, or primary peritoneal cancer | HLA-A*0201, HLA-DP*04 | Phase 1 | NCT03691376 |
| fhB7H3.CAR-Ts | B7H3 | Ovarian cancer | Non-HLA | Phase I/II | NCT05211557 |
| Anti-MUC1 CAR-T cells | MUC1 | Advanced esophageal cancer | Non-HLA | Phase I/II | NCT03706326 |
| Anti-CEA-CAR T | CEA | Colorectal cancer | Non-HLA | Phase I | NCT04513431 |
| anti-MESO CAR-T cells | Mesothelin | Ovarian cancer | Non-HLA | Phase 1/2 | NCT03916679 |
| EpCAM CAR-T cells | EpCAM | Advanced solid tumors | Non-HLA | Phase 1 | NCT02915445 |
| CAR-T cells | PSCA, MUC1, TGFβ, HER2, Mesothelin, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3 | Lung cancer | Non-HLA | Phase 1 | NCT03198052 |
| CD70-targeted CAR-T Therapy | CD70 | Advanced renal cancer | Non-HLA | Phase 1 | NCT05420519 |
| Dual Targeted CAR T-cells | CD20/CD22 | Relapsed or refractory lymphoid malignancies | Non-HLA | Phase 1 | NCT04283006 |
| MOv19-BBz CAR T Cells | Alpha folate receptor | Recurrent high-grade serous ovarian, Fallopian tube, or primary peritoneal cancer | Non-HLA | Phase 1 | NCT03585764 |
| U87 CAR-T | U87 | Pancreatic cancer | Non-HLA | Phase 1 | NCT05605197 |
| LMP1 CAR T-cells | LMP1 | Hematological malignancies | Non-HLA | Phase 1 | NCT04657965 |
| IM83 CAR-T Cells | IM83 | Liver cancer | Non-HLA | Phase 1 | NCT05123209 |
| CAR T cells | ICAM-1 | Relapsed/refractory thyroid cancer | Non-HLA | Phase 1 | NCT04420754 |
| anti- MESO CAR-T cells | Mesothelin | Ovarian cancer | Non-HLA | Phase 1 | NCT03814447 |
| huCART-meso cells | Mesothelin | Pancreatic cancer | Non-HLA | Phase 1 | NCT03323944 |
| Anti-CD33-CAR-transduced T cells | CD33 | Myeloid malignancies | Non-HLA | Phase 1/2 | NCT02958397 |
| Anti-CD7 CAR-T | CD7 | Hematological malignancies | Non-HLA | Phase 2 | NCT05454241 |
| B4T2-001 Autologous CAR T cells | BT-001 | Advanced solid tumor | Non-HLA | Phase 1 | NCT05621486 |
| CEA CAR-T cells | CEA | Solid tumor, lung cancer, colorectal cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, |
Non-HLA | Phase 1/2 | NCT04348643 |
| PSCA- CAR T cells | PSCA | Metastatic castration-resistant prostate cancer | Non-HLA | Phase 1 | NCT03873805 |
| PRGN-3005 Ultra CAR-T cells | BRCA | Advanced, recurrent platinum-resistant ovarian, Fallopian tube or primary peritoneal cancer | Non-HLA | Phase 1 | NCT03907527 |
| P-PSMA-101 CAR-T cells | prostate-specific membrane antigen (PSMA) | Metastatic castration-resistant prostate cancer and advanced salivary gland cancers | Non-HLA | Phase 1 | NCT04249947 |
| BPX-601 CAR-T cells | PSCA | Metastatic castration-resistant prostate cancer | Non-HLA | Phase 1/2 | NCT02744287 |
| Allogeneic γδ T cells in combination with standard drugs | Unknown | Neuroblastoma | Non-HLA | Phase 1 | NCT05400603 |
| CAR γδ T-cells | NKG2DL | Malignant cancer | Non-HLA | Phase 1 | NCT05302037 |
| CAR γδ T-cells | CD7 | Malignant cancer | Non-HLA | Phase 1 | NCT04702841 |
| Autologous and allogeneic γδ T-cells | Unknown | Glioblastoma | Non-HLA | Phase 1/2 | NCT05664243 |
| Allogeneic γδ T-cells | Unknown | Non-Hodgkin’s lymphoma, peripheral T cell lymphoma | Non-HLA | Phase 1 | NCT04696705 |